MINNEAPOLIS, May 12 /PRNewswire-FirstCall/ -- Uroplasty, Inc. , a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunction, announced today that Kenneth M. Peters, M.D., chair of the Department of Urology at Beaumont Hospital in Royal Oak, Michigan, will present preliminary data from the ongoing OrBIT (Overactive Bladder Innovative Therapy) study of the Urgent(R) PC Neuromodulation System at the American Urological Association’s annual meeting. Uroplasty’s Urgent PC system and Macroplastique(R) will also be featured in seven presentations by leading urologists at Uroplasty’s Booth # 3729. The AUA 2008 Annual Meeting will be held from May 17 to May 22 in Orlando, Florida.
“The annual AUA meeting has always been one of the best opportunities for interacting with our customers, and we are excited to host a prestigious line-up of leading urologists who will address the ease-of-use, safety and efficacy of our Urgent PC system for the treatment of urinary frequency, urinary urgency and urge incontinence, symptoms often associated with overactive bladder, and Macroplastique for the treatment of adult female stress urinary incontinence,” said Dave Kaysen, President and Chief Executive Officer of Uroplasty, Inc. “We also eagerly anticipate Dr. Peters’ presentation of the OrBIT trial. As the clinical evidence supporting Urgent PC continues to expand, we fully expect that even greater numbers of patients and physicians alike will seek out the Urgent PC technology’s patient-friendly, highly effective solution to a large and persistent quality of life issue.”
Poster Presentation
In a moderated poster presentation, “A Randomized Multi-Center Study Comparing Percutaneous Tibial Nerve Stimulation (PTNS) with Pharmaceutical Therapy for the Treatment of Overactive Bladder,” Kenneth M. Peters, M.D., will present preliminary results from the ongoing OrBIT clinical study of the Urgent PC system as compared to lterodine LA, the leading pharmaceutical treatment for overactive bladder. The poster session will begin on Tuesday, May 20, 2008 at 1:40 p.m. ET.
Uroplasty Booth Presentations
Throughout the AUA conference, Uroplasty will host seven presentations at its Booth #3729. These include:
About the Urgent PC Neuromodulation System
The Urgent PC neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of urge incontinence, urinary urgency and urinary frequency. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these urinary symptoms. Uroplasty sells the Urgent PC system in the United States, Canada and countries recognizing the CE mark. Outside of the United States, the Urgent PC is also indicated for the treatment of fecal incontinence.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of urinary symptoms often associated with overactive bladder (OAB). We also offer Macroplastique(R) Implants, a urethral bulking agent for the treatment of adult female stress urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.
CONTACT: David Kaysen, President and CEO, or Medi Jiwani, Vice President,
CFO, and Treasurer, both of Uroplasty, Inc., +1-952-426-6140; or investors,
Doug Sherk or Matt Selinger, +1-415-896-6820, or media, Steve DiMattia or
Chris Gale, +1-646-201-5445, all of EVC Group, for Uroplasty, Inc.
Web site: http://www.uroplasty.com/
